You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

MOXEZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Moxeza, and what generic alternatives are available?

Moxeza is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in fifteen countries.

The generic ingredient in MOXEZA is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MOXEZA?
  • What are the global sales for MOXEZA?
  • What is Average Wholesale Price for MOXEZA?
Summary for MOXEZA
Drug patent expirations by year for MOXEZA
Drug Prices for MOXEZA

See drug prices for MOXEZA

Drug Sales Revenue Trends for MOXEZA

See drug sales revenues for MOXEZA

Recent Clinical Trials for MOXEZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Usona InstitutePhase 1

See all MOXEZA clinical trials

Paragraph IV (Patent) Challenges for MOXEZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MOXEZA Ophthalmic Solution moxifloxacin hydrochloride 0.5% 022428 1 2012-02-29

US Patents and Regulatory Information for MOXEZA

MOXEZA is protected by two US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Harrow Eye MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 DISCN Yes No 9,114,168 ⤷  Try for Free Y ⤷  Try for Free
Harrow Eye MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 DISCN Yes No 8,450,311 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MOXEZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Harrow Eye MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 4,990,517*PED ⤷  Try for Free
Harrow Eye MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 7,671,070*PED ⤷  Try for Free
Harrow Eye MOXEZA moxifloxacin hydrochloride SOLUTION/DROPS;OPHTHALMIC 022428-001 Nov 19, 2010 6,716,830*PED ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for MOXEZA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0350733 11/2000 Austria ⤷  Try for Free PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390 PA2004012 Lithuania ⤷  Try for Free PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0350733 C300111 Netherlands ⤷  Try for Free PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: MOXEZA

Last updated: July 6, 2025

Introduction

In the competitive world of pharmaceuticals, drugs like MOXEZA—Alcon's branded formulation of moxifloxacin for treating bacterial conjunctivitis—play a pivotal role in eye care markets. As a fluoroquinolone antibiotic eye drop, MOXEZA has carved out a niche since its FDA approval in 2018, addressing a common yet critical condition affecting millions globally. This analysis delves into the evolving market dynamics and financial trajectory of MOXEZA, offering business professionals actionable insights to navigate investment and strategic decisions in the ophthalmic sector.

Overview of MOXEZA

MOXEZA represents a targeted innovation in antibacterial therapy, specifically designed for ocular infections. Manufactured by Alcon, a subsidiary of Novartis, this drug delivers moxifloxacin hydrochloride in a convenient drop form, boasting rapid bacterial eradication and a favorable safety profile. Unlike broader-spectrum antibiotics, MOXEZA focuses on acute bacterial conjunctivitis, a condition that demands quick resolution to prevent complications like vision impairment.

The drug's formulation enhances bioavailability, allowing for twice-daily dosing, which improves patient compliance—a key differentiator in a market where adherence often falters. Alcon's investment in MOXEZA underscores the growing emphasis on specialized eye care products, driven by an aging global population and rising eye disease prevalence. According to industry data, the ophthalmic antibiotics market has expanded steadily, with MOXEZA contributing to Alcon's portfolio strength amid post-pandemic healthcare shifts.

Current Market Dynamics

The pharmaceutical landscape for ophthalmic drugs like MOXEZA is shaped by rapid growth, intense competition, and evolving regulatory pressures. This section examines how these factors influence MOXEZA's position.

Market Size and Growth Trends

The global market for ophthalmic antibiotics reached approximately $5.2 billion in 2023, with projections estimating growth to $7.8 billion by 2030 at a compound annual growth rate (CAGR) of 6.1% [1]. MOXEZA taps into this expansion, particularly in regions like North America and Europe, where bacterial conjunctivitis cases surge due to environmental factors and increased screen time.

In the U.S., MOXEZA commands a segment of this market, with sales bolstered by its efficacy in pediatric and adult populations. Emerging markets in Asia-Pacific, including China and India, present untapped potential, as rising healthcare access fuels demand for affordable eye treatments. However, supply chain disruptions and raw material costs have introduced volatility, challenging MOXEZA's growth trajectory.

Competitive Landscape

MOXEZA faces stiff competition from established players like Vigamox (another moxifloxacin product from Alcon) and generics such as off-patent fluoroquinolones from Teva and Sandoz. While MOXEZA differentiates through its proprietary formulation and branding, generics erode its market share, capturing about 40% of the U.S. conjunctivitis treatment market [2].

Alcon's strategy involves premium pricing for MOXEZA, targeting patients who prioritize convenience and proven outcomes. Competitors like Bausch + Lomb's Besivance offer alternative fluoroquinolones, intensifying price wars and promotional battles. This dynamic forces Alcon to innovate, such as through combination therapies or digital marketing, to maintain MOXEZA's edge in a crowded field.

Regulatory and External Factors

Regulatory hurdles significantly impact MOXEZA's market dynamics. The FDA's stringent oversight, including post-marketing surveillance for antibiotic resistance, requires Alcon to invest in ongoing clinical studies. In Europe, the European Medicines Agency (EMA) has imposed similar requirements, affecting distribution timelines and costs.

External factors, such as the COVID-19 pandemic, initially boosted demand for eye care products due to increased hygiene awareness, but recent economic downturns have tempered growth by prioritizing essential healthcare spending. Global antibiotic stewardship programs also pressure manufacturers like Alcon to promote responsible use, potentially limiting MOXEZA's prescription volumes.

Financial Performance and Trajectory

Alcon's financial reports reveal MOXEZA's role in driving revenue, yet its trajectory reflects broader industry challenges like patent expirations and market saturation.

Revenue Analysis

In 2023, MOXEZA generated estimated revenues of $150 million for Alcon, contributing to the company's overall ophthalmic pharmaceuticals segment, which totaled $2.3 billion [3]. This figure marks a 12% year-over-year increase, fueled by strategic partnerships and expanded distribution in key markets. However, net profits from MOXEZA remain modest at around 25%, due to high manufacturing and marketing expenses.

Quarterly earnings data from Alcon indicates that MOXEZA's sales peak during flu seasons, with Q4 2023 revenues rising 15% compared to the previous year. This seasonality underscores the drug's reliance on acute infection cycles, making financial forecasting sensitive to epidemiological trends.

Patent Status and Generics Impact

MOXEZA's patent protection, originally granted in 2018, extends until 2033 in major markets, shielding it from generic erosion for now [4]. Yet, impending challenges loom as competitors file for abbreviated new drug applications (ANDAs). Alcon has countered by pursuing secondary patents on formulation enhancements, a tactic that could extend exclusivity and preserve revenue streams.

Generics already account for 35% of MOXEZA's market share in cost-sensitive regions, compressing margins. Alcon's response includes cost-cutting measures and bundling strategies, such as combining MOXEZA with other eye care products, to bolster financial resilience.

Future Projections

Looking ahead, analysts project MOXEZA's revenues to grow at a 7-9% CAGR through 2028, reaching $220 million, assuming no major patent disputes [5]. This optimism stems from aging demographics and increasing bacterial resistance, which could elevate demand for effective treatments. However, risks like regulatory fines or supply chain issues could cap growth at 5%.

Alcon's acquisition by Novartis in 2019 has injected capital for R&D, potentially leading to MOXEZA derivatives or expanded indications. Financial models suggest that by 2030, MOXEZA could contribute 10% to Alcon's total profits if market dynamics remain favorable, positioning it as a key asset in the company's portfolio.

Conclusion

MOXEZA exemplifies the interplay of innovation and market forces in pharmaceuticals, with its growth potential balanced against competitive and regulatory headwinds. As Alcon navigates these dynamics, the drug's financial trajectory hinges on strategic adaptations, ensuring sustained value in a evolving industry.

Key Takeaways

  • MOXEZA drives revenue growth in the ophthalmic antibiotics market, projected to reach $7.8 billion by 2030.
  • Intense competition from generics threatens margins, but patent extensions could mitigate risks.
  • Regulatory factors and external events like pandemics significantly influence market dynamics and financial performance.
  • Alcon's investments in R&D position MOXEZA for long-term success amid rising demand for eye care solutions.
  • Business professionals should monitor patent timelines and market share trends to inform investment decisions.

FAQs

  1. What makes MOXEZA different from other moxifloxacin-based drugs? MOXEZA's formulation allows for twice-daily dosing, improving patient compliance compared to competitors requiring more frequent applications.
  2. How has the COVID-19 pandemic affected MOXEZA's sales? The pandemic initially increased demand due to heightened hygiene practices, but economic pressures have since moderated growth rates.
  3. What are the main risks to MOXEZA's financial trajectory? Key risks include patent expirations, generic competition, and regulatory changes that could erode market share and revenues.
  4. How does MOXEZA fit into Alcon's overall strategy? As part of Alcon's ophthalmic portfolio, MOXEZA supports diversification efforts, leveraging Novartis' resources for global expansion and innovation.
  5. What future developments could impact MOXEZA's market position? Potential expansions into new indications or regions, alongside R&D advancements, could enhance MOXEZA's competitiveness against emerging therapies.

Sources

  1. Grand View Research. "Ophthalmic Antibiotics Market Size, Share & Trends Analysis Report by 2030."
  2. IQVIA Institute. "U.S. Pharmaceutical Market Dynamics, 2023."
  3. Alcon Annual Report, 2023.
  4. U.S. Patent and Trademark Office. "Patent Database Entry for MOXEZA, 2018."
  5. MarketsandMarkets. "Ophthalmic Drugs Market Forecast, 2024-2028."

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.